NuGene International, Inc. Files Provisional Patent Applications to Enhance Wound Treatment by Combining Micro-Current Electro-Active Dressings with Human Adipose-Derived Stem Cell Media
IRVINE, Calif., Oct. 19, 2015 /PRNewswire/ — NuGene International, Inc. (“NuGene”) (NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, announced today that it has filed additional provisional patents to extend the intellectual property around its proprietary stem cell formulations.
The Company has filed two provisional patent applications in the U.S. Patent and Trademark Office for inventions relating to electro-active dressings and bandages. These include inventions combining electro-active sterile dressings and NuGene’s proprietary human adipose derived stem cell culture media.
Human adipose-derived stem cells produce a variety of growth-promoting and healing materials such as growth factors and cytokines. Electro-active wound dressings produce local electric fields by providing electrical half-cells in proximity to treat the skin. Management believes that this innovative intellectual property may combine the benefits of the growth factors and localized electric fields to promote healing of wounds.
“Combining the effects of stem cell media with electro-active dressings may create a powerful new healing regimen,” stated Dr. Sanjay Dhar, NuGene’s Executive Director of Research and Development. “The stimulation provided by electro-active dressings and the properties of human adipose-derived stem cell media may prove to effectively promote better and faster healing with less scar tissue. We believe that seeking protection for our applied research through the patent application process enhances the value of our intellectual property portfolio.”
Skin is the largest organ in the human body. Soon after it is damaged, the body’s repair work starts as new skin tissue is formed. The proliferation and direction of growth factors and stem cells to the site is a key component of this process. NuGene is investigating the enhancement of healing by combining its proprietary stem cell media with micro-current electro-active dressings. The company intends to apply this technology to both medical and aesthetic fields.
About NuGene International, Inc.
NuGene International, Inc. develops, manufactures and markets proprietary regenerative cosmeceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the “next evolution of medical treatments.” The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Service Global Cosmeceuticals Market report. NuGene’s current cosmeceutical products and pharmaceutical products under development are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene’s products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has four patents pending covering 15 unique applications. NuGene’s goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform. For more information on NuGene and its stem cell product lines visit www.nugene.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the “safe harbor” created by those sections. All statements in this release that are not based on historical fact are “forward looking statements.” These statements may be identified by words such as “estimates,” “anticipates,” “projects,” “plans,” “proposes” or “planned,” “seeks,” “may,” “will,” “expects,” “intends,” “believes,” “should,” “would,” “could” and similar expressions or the negative versions thereof and which also may be identified by their context, such as references to “products under development”. All statements that address operating performance or events or developments that NuGene expects or anticipates will occur in the future are forward-looking statements. While management has based any forward looking statements included in this release on its current expectations, we operate in a complex and changing domestic and international competitive environment where new and unanticipated risks may arise, and consequently the information on which such expectations were based, such as expectations of distributor product placements and sales, timing of planned and anticipated product deliveries or product introductions, may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors, including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Quarterly Report on Form 10-Q as filed on August 12, 2015 and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Investor/ Media Relations: